Johnson & Johnson Joins the Litigation Fray on Inflation Reduction Act Drug Negotiation
- July 21, 2023
Johnson & Johnson and its Janssen pharmaceutical companies filed suit July 18 against the U.S. Department of Health and Human Services seeking to block the new Medicare drug price negotiation program under the Inflation Reduction Act of 2022 (IRA).
ARTICLE TAGS
You must be logged in to access this content.